We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Interaction between SNAI2 and MYOD enhances oncogenesis and suppresses differentiation in Fusion Negative Rhabdomyosarcoma.
- Authors
Pomella, Silvia; Sreenivas, Prethish; Gryder, Berkley E.; Wang, Long; Milewski, David; Cassandri, Matteo; Baxi, Kunal; Hensch, Nicole R.; Carcarino, Elena; Song, Young; Chou, Hsien-Chao; Yohe, Marielle E.; Stanton, Benjamin Z.; Amadio, Bruno; Caruana, Ignazio; De Stefanis, Cristiano; De Vito, Rita; Locatelli, Franco; Chen, Yidong; Chen, Eleanor Y.
- Abstract
Rhabdomyosarcoma (RMS) is an aggressive pediatric malignancy of the muscle, that includes Fusion Positive (FP)-RMS harboring PAX3/7-FOXO1 and Fusion Negative (FN)-RMS commonly with RAS pathway mutations. RMS express myogenic master transcription factors MYOD and MYOG yet are unable to terminally differentiate. Here, we report that SNAI2 is highly expressed in FN-RMS, is oncogenic, blocks myogenic differentiation, and promotes growth. MYOD activates SNAI2 transcription via super enhancers with striped 3D contact architecture. Genome wide chromatin binding analysis demonstrates that SNAI2 preferentially binds enhancer elements and competes with MYOD at a subset of myogenic enhancers required for terminal differentiation. SNAI2 also suppresses expression of a muscle differentiation program modulated by MYOG, MEF2, and CDKN1A. Further, RAS/MEK-signaling modulates SNAI2 levels and binding to chromatin, suggesting that the differentiation blockade by oncogenic RAS is mediated in part by SNAI2. Thus, an interplay between SNAI2, MYOD, and RAS prevents myogenic differentiation and promotes tumorigenesis. Rhabdomyosarcomas are tumours blocked in myogenic differentiation, which despite the expression of master muscle regulatory factors, including MYOD, are unable to differentiate. Here, the authors show that SNAI2 is upregulated by MYOD through super enhancers, binds to MYOD target enhancers, and arrests differentiation.
- Subjects
RHABDOMYOSARCOMA; CARCINOGENESIS; NEOPLASTIC cell transformation; TRANSCRIPTION factors; MYOBLASTS; CHROMATIN; MUSCLE growth
- Publication
Nature Communications, 2021, Vol 12, Issue 1, p1
- ISSN
2041-1723
- Publication type
Article
- DOI
10.1038/s41467-020-20386-8